To develop novel therapies for the treatment of traumatic brain injury, as it remains one of the greatest unsolved problems in critical trauma today, and a leading cause of death and major disability.
Cellvation, Inc., is a clinical‐stage biopharmaceutical company developing novel cellular therapeutics for the treatment of traumatic brain injury (“TBI”). Cellvation’s lead program, CEVA101 (bone marrow-derived mononuclear cells) has already demonstrated safety and efficacy in 50+ adults and children with severe TBI (and stroke). The mechanism of action is based on the dampening of the immune response to injury via down-regulation of key pro-inflammatory cytokines. CEVA101 is currently being investigated in a Phase 2 study of children with severe TBI (ClinicalTrials.gov Identifier:NCT01851083), and a Phase 2 study of adults with severe TBI (ClinicalTrials.gov Identifier: NCT02525432).
These studies are supported by grants in excess of $10 million from the National Institutes of Health and the Department of Defense. Cellvation is also developing CEVA‐D, a novel bioreactor that enhances the anti‐inflammatory potency of bone marrow‐derived cells without genetic manipulation. CEVA102 is based on cellular products derived from our proprietary device, CEVA-D, and shall also initially be studied in TBI. Cellvation is a majority‐owned subsidiary of Fortress Biotech (NASDAQ: FBIO) and is based in New York City.